Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis

BACKGROUND: In the RESTORE-IMI 2 trial, imipenem/cilastatin/relebactam (IMI/REL) was noninferior to piperacillin/tazobactam in treating hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. This post hoc analysis was conducted to determine independent predictors of efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Loeches, Ignacio, Shorr, Andrew F, Kollef, Marin H, Du, Jiejun, Losada, Maria C, Paschke, Amanda, DeRyke, C Andrew, Wong, Michael, Jensen, Erin H, Chen, Luke F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297016/
https://www.ncbi.nlm.nih.gov/pubmed/37383243
http://dx.doi.org/10.1093/ofid/ofad225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297016/
https://www.ncbi.nlm.nih.gov/pubmed/37383243
http://dx.doi.org/10.1093/ofid/ofad225

Ejemplares similares